Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Front Psychiatry ; 9: 207, 2018.
Article in English | MEDLINE | ID: mdl-29904359

ABSTRACT

Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. Lithium is the best-established long-term treatment for BD, even though individual response is highly variable. Evidence suggests that some of this variability has a genetic basis. This is supported by the largest genome-wide association study (GWAS) of lithium response to date conducted by the International Consortium on Lithium Genetics (ConLiGen). Recently, we performed the first genome-wide analysis of the involvement of miRNAs in BD and identified nine BD-associated miRNAs. However, it is unknown whether these miRNAs are also associated with lithium response in BD. In the present study, we therefore tested whether common variants at these nine candidate miRNAs contribute to the variance in lithium response in BD. Furthermore, we systematically analyzed whether any other miRNA in the genome is implicated in the response to lithium. For this purpose, we performed gene-based tests for all known miRNA coding genes in the ConLiGen GWAS dataset (n = 2,563 patients) using a set-based testing approach adapted from the versatile gene-based test for GWAS (VEGAS2). In the candidate approach, miR-499a showed a nominally significant association with lithium response, providing some evidence for involvement in both development and treatment of BD. In the genome-wide miRNA analysis, 71 miRNAs showed nominally significant associations with the dichotomous phenotype and 106 with the continuous trait for treatment response. A total of 15 miRNAs revealed nominal significance in both phenotypes with miR-633 showing the strongest association with the continuous trait (p = 9.80E-04) and miR-607 with the dichotomous phenotype (p = 5.79E-04). No association between miRNAs and treatment response to lithium in BD in either of the tested conditions withstood multiple testing correction. Given the limited power of our study, the investigation of miRNAs in larger GWAS samples of BD and lithium response is warranted.

2.
PLoS One ; 8(10): e75333, 2013.
Article in English | MEDLINE | ID: mdl-24098376

ABSTRACT

OBJECTIVE: Chronic alcohol dependence has been associated with disturbed behavior, cerebral atrophy and a low plasma concentration of docosahexaenoic acid (DHA, 22∶6n-3), particularly if liver disease is present. In animal models, excessive alcohol consumption is reported to reduce brain DHA concentration, suggesting disturbed brain DHA metabolism. We hypothesized that brain DHA metabolism also is abnormal in chronic alcoholics. METHODS: We compared 15 non-smoking chronic alcoholics, studied within 7 days of their last drink, with 22 non-smoking healthy controls. Using published neuroimaging methods with positron emission tomography (PET), we measured regional coefficients (K*) and rates (J(in)) of DHA incorporation from plasma into the brain of each group using [1-(11)C]DHA, and regional cerebral blood flow (rCBF) using [(15)O]water. Data were partial volume error corrected for brain atrophy. Plasma unesterified DHA concentration also was quantified. RESULTS: Mean K* for DHA was significantly and widely elevated by 10-20%, and rCBF was elevated by 7%-34%, in alcoholics compared with controls. Unesterified plasma DHA did not differ significantly between groups nor did whole brain J(in), the product of K* and unesterified plasma DHA concentration. DISCUSSION: Significantly higher values of K* for DHA in alcoholics indicate increased brain avidity for DHA, thus a brain DHA metabolic deficit vis-à-vis plasma DHA availability. Higher rCBF in alcoholics suggests increased energy consumption. These changes may reflect a hypermetabolic state related to early alcohol withdrawal, or a general brain metabolic change in chronic alcoholics.


Subject(s)
Alcoholics , Brain/metabolism , Brain/pathology , Cerebrovascular Circulation , Docosahexaenoic Acids/metabolism , Image Processing, Computer-Assisted , Positron-Emission Tomography , Adult , Aged , Atrophy , Brain/blood supply , Brain/diagnostic imaging , Female , Humans , Male , Middle Aged , Time Factors , Young Adult
3.
J Cereb Blood Flow Metab ; 32(4): 676-84, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22167235

ABSTRACT

We developed a novel method to study dopaminergic neurotransmission using positron emission tomography (PET) with [1-(11)C]arachidonic acid ([1-(11)C]AA). Previous preclinical studies have shown the utility of [1-(11)C]AA as a marker of signal transduction coupled to cytosolic phospholipase A(2) (cPLA(2)). Using [1-(11)C]AA and [(15)O]water PET, we measured regional incorporation coefficients K(*) for AA and regional cerebral blood flow (rCBF), respectively, in healthy male volunteers given the D(1)/D(2) agonist (10 or 20 µg/kg subcutaneous) apomorphine. We confirmed a robust central dopaminergic response to apomorphine by observing significant increases in the serum concentration of growth hormone. We observed significant increases, as well as decreases in K(*) and increases in rCBF in response to apomorphine. These changes remained significant after covarying for handedness and apomorphine dosage. The magnitude of increases in K(*) was lower than those in our previous animal experiments, likely reflecting the smaller dose of apomorphine used in the current human study. Changes in K(*) may reflect neuronal signaling downstream of activated D(2)-like receptors coupled to cPLA(2). Changes in rCBF are consistent with previous studies showing net functional effects of D(1)/D(2) activation. [1-(11)C]AA PET may be useful for studying disturbances of dopaminergic neurotransmission in conditions such as Parkinson's disease and schizophrenia.


Subject(s)
Arachidonic Acid/administration & dosage , Brain/blood supply , Brain/metabolism , Cerebrovascular Circulation/physiology , Dopaminergic Neurons/metabolism , Positron-Emission Tomography , Synaptic Transmission/physiology , Adult , Apomorphine/administration & dosage , Brain/diagnostic imaging , Carbon Isotopes/administration & dosage , Dopamine Agonists/administration & dosage , Dopaminergic Neurons/diagnostic imaging , Functional Laterality/physiology , Group IV Phospholipases A2/metabolism , Humans , Male , Middle Aged , Parkinson Disease/metabolism , Parkinson Disease/physiopathology , Potassium/metabolism , Radiography , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolism , Schizophrenia/metabolism , Schizophrenia/physiopathology , Synaptic Transmission/drug effects
4.
J Lipid Res ; 50(7): 1259-68, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19112173

ABSTRACT

Docosahexaenoic acid (DHA; 22:6n-3) is a critical constituent of the brain, but its metabolism has not been measured in the human brain in vivo. In monkeys, using positron emission tomography (PET), we first showed that intravenously injected [1-(11)C]DHA mostly entered nonbrain organs, with approximately 0.5% entering the brain. Then, using PET and intravenous [1-(11)C]DHA in 14 healthy adult humans, we quantitatively imaged regional rates of incorporation (K*) of DHA. We also imaged regional cerebral blood flow (rCBF) using PET and intravenous [(15)O]water. Values of K* for DHA were higher in gray than white matter regions and correlated significantly with values of rCBF in 12 of 14 subjects despite evidence that rCBF does not directly influence K*. For the entire human brain, the net DHA incorporation rate J(in), the product of K*, and the unesterified plasma DHA concentration equaled 3.8 +/- 1.7 mg/day. This net rate is equivalent to the net rate of DHA consumption by brain and, considering the reported amount of DHA in brain, indicates that the half-life of DHA in the human brain approximates 2.5 years. Thus, PET with [1-(11)C]DHA can be used to quantify regional and global human brain DHA metabolism in relation to health and disease.


Subject(s)
Brain/metabolism , Docosahexaenoic Acids/metabolism , Positron-Emission Tomography/methods , Adult , Animals , Brain/anatomy & histology , Brain Mapping , Carbon Radioisotopes/metabolism , Docosahexaenoic Acids/chemistry , Female , Haplorhini , Humans , Male , Middle Aged , Radiopharmaceuticals/metabolism , Regional Blood Flow , Tissue Distribution , Young Adult
5.
J Nucl Med ; 49(9): 1414-21, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18703605

ABSTRACT

UNLABELLED: Incorporation coefficients (K*) of arachidonic acid (AA) in the brain are increased in a rat model of neuroinflammation, as are other markers of AA metabolism. Data also indicate that neuroinflammation contributes to Alzheimer's disease (AD). On the basis of these observations, K* for AA was hypothesized to be elevated in patients with AD. METHODS: A total of 8 patients with AD with an average (+/-SD) Mini-Mental State Examination score of 14.7+/-8.4 (mean age, 71.7+/-11.2 y) and 9 controls with a normal Mini-Mental State Examination score (mean age, 68.7+/-5.6 y) were studied. Each subject received a (15)O-water PET scan of regional cerebral blood flow, followed after 15 min by a 1-(11)C-AA scan of regional K* for AA. RESULTS: In the patients with AD, compared with control subjects, global gray matter K* for AA (corrected or uncorrected for the partial-volume error [PVE]) was significantly elevated, whereas only PVE-uncorrected global cerebral blood flow was reduced significantly (P<0.05). A false-discovery-rate procedure indicated that PVE-corrected K* for AA was increased in 78 of 90 identified hemispheric gray matter regions. PVE-corrected regional cerebral blood flow, although decreased in 12 regions at P<0.01 by an unpaired t test, did not survive the false-discovery-rate procedure. The surviving K* increments were widespread in the neocortex but were absent in caudate, pallidum, and thalamic regions. CONCLUSION: These preliminary results show that K* for AA is widely elevated in the AD brain, particularly in regions reported to have high densities of senile (neuritic) plaques with activated microglia. To the extent that the elevations represent upregulated AA metabolism associated with neuroinflammation, PET with 1-(11)C-AA could be used to examine neuroinflammation in patients with AD and other brain diseases.


Subject(s)
Alzheimer Disease/diagnostic imaging , Arachidonic Acid , Brain/diagnostic imaging , Encephalitis/diagnostic imaging , Positron-Emission Tomography/methods , Aged , Aged, 80 and over , Alzheimer Disease/complications , Arachidonic Acid/chemistry , Carbon Radioisotopes/chemistry , Encephalitis/complications , Female , Humans , Isotope Labeling/methods , Male , Middle Aged , Radiopharmaceuticals/chemical synthesis , Reproducibility of Results , Sensitivity and Specificity
6.
Int J Neuropsychopharmacol ; 11(7): 957-69, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18570702

ABSTRACT

Acute d-amphetamine (d-Amph) administration to rats leads to the release of arachidonic acid (AA, 20:4n-6) as a second messenger following indirect agonism at dopamine D2-like receptors in the brain. We hypothesized that chronically administered d-Amph in rats also would alter brain AA metabolism and signalling. To test this, adult male rats were injected i.p. daily for 2 wk with saline or 2.5 mg/kg d-Amph. After a 1-d washout, the unanaesthetized rats were injected acutely with i.v. saline, 1 mg/kg quinpirole (a D2-like receptor agonist) or 5.0 mg/kg SKF-38393 (a D1-like receptor agonist), followed by i.v. [1-14C]AA. The AA incorporation coefficient k* (brain radioactivity/integrated plasma radioactivity), a marker of AA signalling and metabolism, was quantified using autoradiography in each of 62 brain regions. Compared with chronic saline, chronic d-Amph widely decreased baseline values of k* in brain regions having D2-like receptors. On the other hand, chronic amphetamine did not alter the k* responses to quinpirole seen in chronic saline-treated rats. SKF-38393 had minimal effects on k* in both chronic saline-treated and amphetamine-treated rats, consistent with D1-like receptors not being coupled to AA signalling. The ability of chronic d-Amph after 1-d washout to down-regulate baseline values of k* probably reflects neuroplastic changes in brain AA signalling, and may correspond to depressive behaviours noted following withdrawal from chronic amphetamine in humans and in rats.


Subject(s)
Arachidonic Acid/metabolism , Brain Chemistry/drug effects , Central Nervous System Stimulants/pharmacology , Dextroamphetamine/pharmacology , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology , Animals , Arachidonic Acid/pharmacokinetics , Autoradiography , Biomarkers/analysis , Biomarkers/metabolism , Central Nervous System Stimulants/administration & dosage , Depression, Chemical , Dextroamphetamine/administration & dosage , Dopamine Agonists/pharmacology , Fatty Acids, Nonesterified/blood , Half-Life , Image Processing, Computer-Assisted , Injections, Intraperitoneal , Male , Quinpirole/pharmacology , Rats , Rats, Inbred F344 , Receptors, Dopamine D2/agonists , Receptors, Phospholipase A2/drug effects , Signal Transduction/drug effects
7.
Neuroimage ; 34(4): 1342-51, 2007 Feb 15.
Article in English | MEDLINE | ID: mdl-17196833

ABSTRACT

BACKGROUND: Arachidonic acid (AA, 20:4n-6), an important second messenger, is released from membrane phospholipid following receptor mediated activation of phospholipase A(2) (PLA(2)). This signaling process can be imaged in brain as a regional brain AA incorporation coefficient K*. HYPOTHESIS: K* will be increased in brain visual areas of subjects submitted to visual stimulation. SUBJECTS AND METHODS: Regional values of K* were measured with positron emission tomography (PET), following the intravenous injection of [1-(11)C]AA, in 16 healthy volunteers subjected to visual stimulation at flash frequencies 2.9 Hz (8 subjects) or 7.8 Hz (8 subjects), compared with the dark (0 Hz) condition. Regional cerebral blood flow (rCBF) was measured with intravenous [(15)O]water under comparable conditions. RESULTS: During flash stimulation at 2.9 Hz or 7.8 Hz vs. 0 Hz, K* was increased significantly by 2.3-8.9% in Brodmann areas 17, 18 and 19, and in additional frontal, parietal and temporal cortical regions. rCBF was increased significantly by 3.1-22%, often in comparable regions. Increments at 7.8 Hz often exceeded those at 2.9 Hz for both K* and rCBF. Decrements in both parameters also were produced, particularly in frontal brain regions. CONCLUSIONS: AA plays a role in signaling processes provoked by visual stimulation, since visual stimulation at flash frequencies of 2.9 and 7.8 Hz compared to 0 Hz modifies both K* for AA and rCBF in visual and related areas of the human brain. The two-stimulus condition paradigm of this study might be used with PET to image effects of other functional activations and of drugs on brain signaling via AA.


Subject(s)
Arachidonic Acid/physiology , Brain/diagnostic imaging , Photic Stimulation , Positron-Emission Tomography/methods , Adult , Brain/physiology , Carbon Radioisotopes , Female , Humans , Image Processing, Computer-Assisted , Male , Phospholipases A/metabolism , Radiography , Second Messenger Systems , Signal Transduction
9.
J Cereb Blood Flow Metab ; 26(11): 1378-88, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16511499

ABSTRACT

In rat brain, dopaminergic D(2)-like but not D(1)-like receptors can be coupled to phospholipase A(2) (PLA(2)) activation, to release the second messenger, arachidonic acid (AA, 20:4n-6), from membrane phospholipids. In this study, we hypothesized that D-amphetamine, a dopamine-releasing agent, could initiate such AA signaling. The incorporation coefficient, k* (brain radioactivity/integrated plasma radioactivity) for AA, a marker of the signal, was determined in 62 brain regions of unanesthetized rats that were administered i.p. saline, D-amphetamine (2.5 or 0.5 mg/kg i.p.), or the D(2)-like receptor antagonist raclopride (6 mg/kg, i.v.) before saline or 2.5 mg/kg D-amphetamine. After injecting [1-(14)C]AA intravenously, k* was measured by quantitative autoradiography. Compared to saline-treated controls, D-amphetamine 2.5 mg/kg i.p. increased k* significantly in 27 brain areas rich in D(2)-like receptors. Significant increases were evident in neocortical, extrapyramidal, and limbic regions. Pretreatment with raclopride blocked the increments, but raclopride alone did not alter baseline values of k*. In independent experiments, D-amphetamine 0.5 mg/kg i.p. increased k* significantly in only seven regions, including the nucleus accumbens and layer IV neocortical regions. These results indicate that D-amphetamine can indirectly activate brain PLA(2) in the unanesthetized rat, and that activation is initiated entirely at D(2)-like receptors. D-Amphetamine's low-dose effects are consistent with other evidence that the nucleus accumbens, considered a reward center, is particularly sensitive to the drug.


Subject(s)
Arachidonic Acid/physiology , Dextroamphetamine/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Receptors, Dopamine D2/agonists , Signal Transduction/drug effects , Algorithms , Animals , Arachidonic Acid/pharmacokinetics , Autoradiography , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Glucose/metabolism , Kinetics , Male , Nucleus Accumbens/drug effects , Nucleus Accumbens/physiology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Raclopride/pharmacology , Rats , Rats, Inbred F344
SELECTION OF CITATIONS
SEARCH DETAIL
...